Baird analyst Colleen Kusy raised the firm’s price target on Apellis to $96 from $86 and keeps an Outperform rating on the shares. The firm noted the company reported better-than-expected, positive results for subq pegcetacoplan in two rare, serious kidney diseases (C3G/IC-MPGN) which adds $50M peak opportunity to Baird’s model.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis price target lowered to $83 from $92 at H.C. Wainwright
- Apellis reports Q2 EPS (30c), consensus (32c)
- Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results
- Apellis FAERS update doesn’t change Jefferies’ view on Syfovre’s safety
- Apellis price target lowered to $86 from $100 at Baird